{
  "meta": {
    "title": "93_Plasma_Cell_Disorders",
    "url": "https://brainandscalpel.vercel.app/93-plasma-cell-disorders-01a79618.html",
    "scrapedAt": "2025-11-30T12:29:19.209Z"
  },
  "questions": [
    {
      "text": "What is the most common symptom seen in patients with multiple myeloma?",
      "choices": [
        {
          "id": 1,
          "text": "Easy fatigability"
        },
        {
          "id": 2,
          "text": "Bone pain"
        },
        {
          "id": 3,
          "text": "Oliguria"
        },
        {
          "id": 4,
          "text": "Fever"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p><strong>Bone pain</strong> is the <strong>most common</strong> symptom in&nbsp;<strong>multiple myeloma</strong>.&nbsp;</p>\n<p>Multiple myeloma is a plasma cell malignancy in which there is an increased proliferation of monoclonal plasma cells. There is an increased production of monoclonal paraprotein (M protein).&nbsp;</p>\n<p>Clinical features of multiple myeloma:</p>\n<ol>\n<li><strong>Bone pain</strong> (most common):\n<ul>\n<li>Due to proliferation of tumor cells, activation of osteoclasts that destroy bone, and suppression of osteoblasts that form new bone.</li>\n<li>Persistent localized pain in a patient with myeloma usually signifies a pathological fracture.</li>\n</ul>\n</li>\n<li><strong>Fever </strong>due to recurrent bacterial infections (second most common)</li>\n<li><strong>Acute kidney injury</strong> due to:\n<ul>\n<li><strong>Hypercalcemia</strong> (most common)</li>\n<li>Amyloid deposits</li>\n<li>Hyperuricemia</li>\n<li>Recurrent infections</li>\n<li>Infiltration of the kidney by myeloma cells</li>\n</ul>\n</li>\n<li><strong>Normocytic-normochromic anemia</strong> due to:\n<ul>\n<li>Replacement of normal marrow by expanding tumor cells</li>\n<li>Inhibition of hematopoiesis by factors made by the tumor</li>\n<li>Reduced production of erythropoietin by the kidney</li>\n</ul>\n</li>\n</ol>\n<div class=\"page\" title=\"Page 844\">\n<div class=\"section\">\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p><strong>Myeloma defining events</strong> (MDE) include the presence of one or more features such as hypercalcemia, renal failure, anemia and lytic bone lesions.</p>\n</div>\n</div>\n</div>\n</div>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB4201",
      "difficulty": "easy"
    },
    {
      "text": "Which of the following is true about multiple myeloma?",
      "choices": [
        {
          "id": 1,
          "text": "Increased monoclonal IgG1 causes hyperviscosity syndrome"
        },
        {
          "id": 2,
          "text": "Monoclonal gammopathy of undetermined significance mostly progresses to multiple myeloma"
        },
        {
          "id": 3,
          "text": "There is decreased anion gap"
        },
        {
          "id": 4,
          "text": "Radioisotope bone scanning can be used for diagnosis"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p>There is<strong> decreased anion gap</strong> in multiple myeloma due to the<strong> M protein</strong>.&nbsp;</p>\n<p>Anion gap in the serum is calculated as Na⁺ &ndash; (Cl<sup>&ndash;</sup> +HCO3<sup>&ndash;</sup>).</p>\n<p>The M protein is <strong>cationic</strong>, resulting in the retention of chloride causing decreased anion gap.</p>\n<p>Only <strong>1% </strong>of patients with <strong>monoclonal gammopathy of undetermined significance</strong> (MGUS) go on to <strong>develop</strong> multiple myeloma.&nbsp;<strong>Hyperviscosity </strong>symptoms<strong>&nbsp;</strong>in<strong> multiple myeloma</strong>&nbsp;occurs due to excessive production of M proteins, usually of <strong>IgG3 or IgA</strong> subtype.&nbsp;<strong>Waldenstrom macroglobulinemia </strong>(IgM myeloma) is the most common cause for hyperviscosity syndrome&nbsp;due to excess<strong> IgM paraprotein</strong> in these cases.</p>\n<p>Radioisotopic bone scanning is less useful in diagnosis because the bone lesions are lytic in nature and are rarely associated with osteoblastic new bone formation.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB4199",
      "difficulty": "hard"
    },
    {
      "text": "A 72-year-old man presented with complaints of fatiguability and chronic lower back pain. Laboratory findings are as follows. What is the most likely diagnosis?<div class='question-desc-html'><p>Hemoglobin - 9 g/dl </p>\n<p>Serum calcium - 11.5 mg/dl </p>\n<p>Serum M protein - 50 g/l</p>\n<p>Bone marrow biopsy showed 15 % clonal plasma cells</p></div>",
      "choices": [
        {
          "id": 1,
          "text": "Multiple myeloma"
        },
        {
          "id": 2,
          "text": "Monoclonal gammopathy of unknown significance"
        },
        {
          "id": 3,
          "text": "Smoldering multiple myeloma"
        },
        {
          "id": 4,
          "text": "Non-secretory myeloma"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p>In this scenario, the patient has <strong>increased M protein</strong> (&gt;30g/l), bone marrow <strong>clonal plasma cells &gt;10%</strong>, and evidence of end-organ damage (fatiguability and back pain). The most likely diagnosis is <strong>multiple myeloma</strong>.</p>\n<p>Diagnostic criteria for plasma cell disorders:</p>\n<table>\n<tbody>\n<tr>\n<td>Criteria</td>\n<td>Monoclonal gammopathy of undetermined significance (MGUS)</td>\n<td>Smoldering multiple myeloma (asymptomatic myeloma)</td>\n<td>Multiple myeloma</td>\n<td>Non-secretory myeloma</td>\n</tr>\n<tr>\n<td>M protein (&gt;30g/l)</td>\n<td>No</td>\n<td>Yes</td>\n<td>Yes</td>\n<td>No</td>\n</tr>\n<tr>\n<td>Bone marrow plasma cells (&gt;10%)</td>\n<td>No</td>\n<td>Yes </td>\n<td>Yes</td>\n<td>Yes</td>\n</tr>\n<tr>\n<td>\n<p>End organ damage <strong>(CRAB)</strong></p>\n<p>S. <strong>C</strong>alcium &gt;11 mg/dl</p>\n<p><strong>R</strong>enal, S. Creatinine &gt;2 mg/dl</p>\n<p><strong>A</strong>nemia, Hemoglobin &lt;10g/dl</p>\n<p>Lytic <strong>b</strong>one lesions</p>\n</td>\n<td>No</td>\n<td>No</td>\n<td>Yes</td>\n<td>Yes</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<p>Note: Solitary plasmacytoma of bone has only a single area of bone destruction due to clonal plasma cells, no M protein, bone marrow appears normal, and no end-organ damage.</p>\n<p>Plasma cell leukemia is an aggressive plasma cell proliferative disorder with &gt;20% abnormal plasma cells in the peripheral blood.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC2930",
      "difficulty": "medium"
    },
    {
      "text": "What is the most common cause of renal failure in patients with multiple myeloma?",
      "choices": [
        {
          "id": 1,
          "text": "Light chain deposition"
        },
        {
          "id": 2,
          "text": "Amyloidosis"
        },
        {
          "id": 3,
          "text": "Recurrent infections"
        },
        {
          "id": 4,
          "text": "Hypercalcemia"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<p><strong>Hypercalcemia</strong> is the <strong>most common cause</strong> of <strong>renal failure</strong> in multiple myeloma.</p>\n<p>The <strong>second most common</strong> cause of renal failure in multiple myeloma is<strong> light chain cast nephropathy</strong>. The most common type of myeloma causing renal failure is light chain myeloma.&nbsp;</p>\n<p>Mechanisms involved in acute kidney injury are:</p>\n<ul>\n<li>Hypercalcemia</li>\n<li>Amyloid deposits</li>\n<li>Hyperuricemia</li>\n<li>Recurrent infections</li>\n<li>Infiltration of the kidney by myeloma cells</li>\n<li>Tubular damage by excretion of light chains (Fanconi's syndrome)</li>\n</ul>\n<p>&nbsp;</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB4202",
      "difficulty": "medium"
    },
    {
      "text": "A patient was brought to the hospital with dehydration and generalised weakness. He was diagnosed with multiple myeloma 2 years ago. Investigations revealed metabolic acidosis and hypokalemia. Urine analysis showed a pH of 5.1, glycosuria, and proteinuria. What is the most likely diagnosis?",
      "choices": [
        {
          "id": 1,
          "text": "Renal tubular acidosis type 1"
        },
        {
          "id": 2,
          "text": "Adult Fanconi's syndrome"
        },
        {
          "id": 3,
          "text": "Renal tubular acidosis type 4"
        },
        {
          "id": 4,
          "text": "Alport syndrome"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p>In this patient with&nbsp;hypokalemia and urine pH of 5.1, type 2 renal tubular acidosis&nbsp;(<strong>adult Fanconi&rsquo;s syndrome</strong>) is the likely diagnosis.&nbsp;It is commonly associated with multiple myeloma.</p>\n<p>Normally, light chains are filtered, reabsorbed in the proximal tubules, and catabolized. In multiple myeloma, there is an<strong> increased</strong> amount of <strong>light chains</strong> and the tubular cells are overloaded.&nbsp;</p>\n<p>This leads to<strong> proximal tubular damage</strong> either directly from light chain toxic effects or indirectly from the release of intracellular lysosomal enzymes.</p>\n<p>Clinical features of renal tubular acidosis type 2:</p>\n<ul>\n<li>Metabolic acidosis</li>\n<li>Urine pH &lt;5.3</li>\n<li>Proteinuria (only light chains)</li>\n<li>Glycosuria</li>\n<li>Aminoaciduria</li>\n</ul>\n<p>Alport's syndrome is characterised by hematuria, hearing loss and eye abnormalities.</p><hr><h3>Related Pearl: Characteristics of renal tubular acidosis (RTA)</h3><table>\n<tbody>\n<tr>\n<td rowspan=\"2\">&nbsp;&nbsp;</td>\n<td colspan=\"2\">Hypokalemic RTA&nbsp;</td>\n<td>Hyperkalemic RTA</td>\n</tr>\n<tr>\n<td>\n<p>Type 1 RTA</p>\n</td>\n<td>Type 2 RTA&nbsp;</td>\n<td>\n<p>Type 4 RTA</p>\n<p>Most Common</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Primary</p>\n<p>defect</p>\n</td>\n<td>\n<p>Impaired distal acidification</p>\n</td>\n<td>\n<p>Reduced proximal</p>\n<p>HCO<sub>3</sub>&nbsp;resorption</p>\n</td>\n<td>Decreased aldosterone secretion or aldosterone resistance</td>\n</tr>\n<tr>\n<td>\n<p>Plasma HCO3</p>\n<p>(mEq/L)</p>\n</td>\n<td>&nbsp;<span class=\"symbol\">&lt;</span>15</td>\n<td>12 to 20</td>\n<td>&gt;17</td>\n</tr>\n<tr>\n<td>Plasma potassium</td>\n<td>\n<p>&nbsp; Low</p>\n<p>(normalizes with alkalinization)</p>\n</td>\n<td>\n<p>&nbsp;Low</p>\n<p>(Decreased further by alkalinization)</p>\n</td>\n<td>\n<p><strong>High</strong></p>\n<p>(correcting the hyperkalemia alone will improve the acidosis by increasing ammonium availability)</p>\n</td>\n</tr>\n<tr>\n<td>Urine pH</td>\n<td>&gt;5.5</td>\n<td>\n<p>&gt; 5.3 if the serum HCO<sub>3&nbsp;</sub>exceeds the tubule's&nbsp;HCO<sub>3&nbsp;</sub></p>\n<p>reabsorptive threshold.</p>\n<p><strong>&lt; 5.3</strong> when the serum HCO<sub>3</sub>&nbsp;is reduced to levels that can be largely reabsorbed despite defective proximal tubule reabsorptive mechanisms.</p>\n</td>\n<td>&lt;5.5</td>\n</tr>\n<tr>\n<td>\n<p>Urine</p>\n<p>anion gap</p>\n</td>\n<td>Positive</td>\n<td>Negative</td>\n<td>Positive</td>\n</tr>\n<tr>\n<td>\n<p>Nephrolithiasis/ Nephrocalcinosis</p>\n</td>\n<td>&nbsp;Yes</td>\n<td>&nbsp;No</td>\n<td>&nbsp;No</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<p>&nbsp;</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB4204",
      "difficulty": "medium"
    },
    {
      "text": "What is the immunophenotype of tumor cells in multiple myeloma?",
      "choices": [
        {
          "id": 1,
          "text": "CD19"
        },
        {
          "id": 2,
          "text": "CD38"
        },
        {
          "id": 3,
          "text": "CD 20"
        },
        {
          "id": 4,
          "text": "CD 5"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p>The immunophenotype of tumor cells in <strong>multiple myeloma</strong> is <strong>CD38 </strong>and<strong> CD138.</strong></p>\n<p>Multiple myeloma is derived from plasma cells in which B cell markers (CD19, CD20) are lost.</p>\n<p>Immunophenotype of tumor cells in lymphoplasmacytic lymphoma / Waldenstrom's macroglobulinemia is CD19, CD20, surface IgM+, CD38.&nbsp;A lymphoplasmacytic cell retains B cell markers and carries plasma cell markers.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB4205",
      "difficulty": "medium"
    },
    {
      "text": "A 45-year-old patient presented with multiple fractures and bone pain. Serum electrophoresis revealed elevated serum M protein. What does it most likely to constitute?",
      "choices": [
        {
          "id": 1,
          "text": "Ig M"
        },
        {
          "id": 2,
          "text": "Ig G"
        },
        {
          "id": 3,
          "text": "Albumin"
        },
        {
          "id": 4,
          "text": "Lamda light chains"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p>In the above clinical scenario,&nbsp;the patient most likely has multiple myeloma as there are&nbsp;<strong>pathological fractures</strong>&nbsp;and <strong>elevated M protein</strong>. Serum M protein is likely to constitute <strong>IgG</strong>.</p>\n<p>The serum M component is IgG in 53% of patients, IgA in 25%, and IgD in 1%.</p>\n<p>Serum <strong>Ig</strong><strong>M</strong> is elevated in <strong>Waldenstrom's macroglobulinemia</strong> (lymphoplasmacytic lymphoma).</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC2932",
      "difficulty": "medium"
    },
    {
      "text": "A 60-year-old man presented with fatigue and back pain since 3 months. Investigations were done and are as follows. What is the most likely diagnosis?<div class='question-desc-html'><p>Hemoglobin=7 g/dl</p>\n<p>Total leukocyte count =9000/cu.mm</p>\n<p>Serum protein = 6 gm%&nbsp;</p>\n<p>Serum albumin = 3.5 g/dl&nbsp;</p>\n<p>Serum protein electrophoresis (SPEP) shows the given pattern</p>\n<p>Bone marrow clonal plasmacytosis = 15%</p></div>",
      "choices": [
        {
          "id": 1,
          "text": "Multiple myeloma"
        },
        {
          "id": 2,
          "text": "Lymphoplasmacytic lymphoma"
        },
        {
          "id": 3,
          "text": "Monoclonal gammopathy of undetermined significance"
        },
        {
          "id": 4,
          "text": "Non-secretory myeloma"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<p>In the given clinical scenario, the patient has&nbsp;<strong>normal SPEP</strong> and clonal plasmacytosis. The most likely diagnosis is <strong>non-secretory myeloma</strong>.</p>\n<p>Non-secretory myeloma is characterised by the <strong>absence</strong> of <strong>M protein</strong> in the serum or urine.&nbsp;Bone marrow clonal plasmacytosis &gt; 10% and myeloma defining symptoms.</p>\n<p>Option A: In<strong> multiple myeloma</strong>, SPEP demonstrates a <strong>sharp peak</strong> (church spire or <strong>M band</strong>) in the gamma globulin region, as shown below.</p><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/3c5da67cfc2c404fbc297a8d109b53dax1280x1233.JPEG\" alt=\"Explanation Image\"><p>Option B: Lymphoplasmacytic lymphoma (Waldenstrom's macroglobulinemia) also demonstrates a localized peak (<strong>M band</strong>) in the gamma globulin region. Immunofixation is required to identify the type of immunoglobulin.</p>\n<p>Option C: Monoclonal gammopathy of undetermined significance (MGUS) does not present with myeloma-defining symptoms. Clonal bone marrow cells will be less than 10%</p>",
      "question_images": [
        "https://cdn1.dailyrounds.org/uploads/1d360e5a02a5420da1642063594ef076.JPEG"
      ],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC2879",
      "difficulty": "hard"
    },
    {
      "text": "A 69-year-old business tycoon is diagnosed with multiple myeloma. He is worried about his business empire and asks you how long he will survive. Which of the following is the best predictor for this?",
      "choices": [
        {
          "id": 1,
          "text": "Durie-Salmon staging system"
        },
        {
          "id": 2,
          "text": "Percentage of circulating plasma cells"
        },
        {
          "id": 3,
          "text": "Beta-2 microglobulin levels"
        },
        {
          "id": 4,
          "text": "Plasma cell labeling index"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p><strong>Serum &beta;2-microglobulin</strong>&nbsp;levels are the <strong>best modality</strong> to predict the median <strong>survival</strong> period.&nbsp;</p>\n<p>Albumin levels alone cannot be used to predict the median survival period. It is used in combination with&nbsp;&beta;2-microglobulin for risk stratification.</p>\n<p>Patients with &beta;2-microglobulin levels <strong>&lt;3.5 mg/L</strong>&nbsp;and albumin levels &gt; 3.5 g/dl have a median survival period of<strong> 5 years. </strong>Those with levels <strong>&gt;3.5 mg/L </strong>and albumin &lt; 3.5 g/dl have a survival period of fewer than <strong>2 years.</strong></p>\n<p>Durie-Salmon staging is unable to predict outcomes with newer agents. Hence it is no longer used.</p>\n<p>Factors associated with poor prognosis:&nbsp;</p>\n<ul>\n<li>Plasma cell labeling index&nbsp;</li>\n<li>Chromosomal aberrations</li>\n<li>Circulating plasma cells</li>\n<li>Performance status</li>\n<li>Highly elevated LDH</li>\n<li>Extramedullary disease</li>\n<li>De novo plasma cell leukemia</li>\n</ul>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB4206",
      "difficulty": "medium"
    },
    {
      "text": "In patients with multiple myeloma, the presence of which of the following is associated with a poor prognosis?",
      "choices": [
        {
          "id": 1,
          "text": "t (11,14)"
        },
        {
          "id": 2,
          "text": "t (6,14)"
        },
        {
          "id": 3,
          "text": "17p deletion"
        },
        {
          "id": 4,
          "text": "13q deletion"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p><strong>17p deletion</strong> is associated with<strong>&nbsp;</strong>a <strong>poor prognosis</strong>&nbsp;in multiple myeloma.</p>\n<p>Chromosomal abnormalities in multiple myeloma are classified as follows:</p>\n<p><strong>Standard risk</strong> (6-7 years survival):&nbsp;</p>\n<ul>\n<li>t(11;14) (most common)</li>\n<li>t(6;14)</li>\n<li>13q deletion</li>\n</ul>\n<p><strong>High risk</strong> (2-3 years survival):&nbsp;</p>\n<ul>\n<li>17p deletion</li>\n<li>t(4;14)&nbsp;</li>\n<li>t(14;16)</li>\n<li>t(14;20)</li>\n</ul>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB4207",
      "difficulty": "medium"
    },
    {
      "text": "An X-ray skull of a patient with marked hypercalcemia is shown below. Which of the following laboratory parameters is consistent with his diagnosis?",
      "choices": [
        {
          "id": 1,
          "text": "High alkaline phosphatase and normal ESR"
        },
        {
          "id": 2,
          "text": "High alkaline phosphatase and elevated ESR"
        },
        {
          "id": 3,
          "text": "Normal alkaline phosphatase and normal ESR"
        },
        {
          "id": 4,
          "text": "Normal alkaline phosphatase and elevated ESR"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<p>In the above clinical scenario, hypercalcemia along with the skull demonstrating typical '<strong>punched out</strong>' <strong>lesions</strong>&nbsp;is characteristic of multiple myeloma. <strong>Normal</strong> <strong>alkaline phosphatase </strong>and&nbsp;<strong>elevated ESR</strong> are consistent with <strong>multiple myeloma.</strong></p>\n<p>Multiple myeloma is a malignant plasma cell dyscrasia with the proliferation of&nbsp;<strong>plasma cells</strong>&nbsp;derived from a&nbsp;<strong>single clone.</strong>&nbsp;It is associated with an&nbsp;<strong>increased osteoclast activity</strong>&nbsp;with suppression of osteoblast activity, causing&nbsp;<strong>punched-out lytic lesions&nbsp;</strong>in the bone and&nbsp;<strong>hypercalcemia</strong>.</p>\n<p>Signs and symptoms:</p>\n<ul>\n<li><strong>Bone pain</strong>&nbsp;is the most common symptom</li>\n<li>Pathologic fractures</li>\n<li>Recurrent bacterial infections</li>\n<li>Renal failure</li>\n<li><strong>Normocytic normochromic anemia</strong>,&nbsp;<strong>elevated ESR</strong>, hypercalcemia,&nbsp;<strong>normal ALP&nbsp;</strong>(ALP is a marker of&nbsp;bone growth and hence is&nbsp;not increased&nbsp;in multiple myeloma)</li>\n<li>Radiography:&nbsp;<strong>Punched-out lytic&nbsp;</strong>lesions on X-ray. The lesions are <strong>purely osteolytic</strong>&nbsp;with little or no osteoblastic activity. Hence alkaline phosphatase&nbsp;(ALP) is normal. The most common site of lytic lesion in multiple myeloma is the vertebral column.</li>\n<li>Electrophoresis:&nbsp;<strong>M spikes</strong></li>\n<li>Urinalysis:&nbsp;<strong>Bence Jones proteinuria</strong></li>\n<li>Bone marrow biopsy:<strong>&nbsp;Plasma cells</strong></li>\n</ul><hr><h3>Related Pearl: International Staging System (ISS) for multiple myeloma:</h3><p><strong>International Staging System (ISS) for multiple myeloma:</strong></p>\n<table>\n<tbody>\n<tr>\n<td>&beta;2 microglobulin (mg/dL) and albumin (g/dL) level</td>\n<td>Stage</td>\n<td>Median survival months</td>\n</tr>\n<tr>\n<td>\n<p>&beta;2M &lt; 3.5</p>\n<p>alb&nbsp;&ge;3.5</p>\n</td>\n<td>I</td>\n<td>62</td>\n</tr>\n<tr>\n<td>\n<p>&beta;2M &lt; 3.5, alb &lt; 3.5</p>\n<p>or&nbsp;&beta;2M = 3.5-5.5</p>\n</td>\n<td>II</td>\n<td>44</td>\n</tr>\n<tr>\n<td>&beta;2M &gt; 5.5</td>\n<td>III</td>\n<td>29</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<p>ISS is the most widely used method of assesing prognosis in multiple myeloma.</p><hr><h3>Related Pearl: Causes of lytic lesions in the skull</h3><ul>\n<li>Eosinophilic granuloma (geographic lytic lesions in the vault of skull with beveled edges)</li>\n<li>Multiple myeloma (punched out lytic lesion)</li>\n<li>Langerhans Cell Histiocytosis (permeative lesions)</li>\n<li>Hyperparathyroidism (salt and pepper skull)</li>\n<li>Metastasis</li>\n<li>Lymphoma</li>\n<li>Tuberculosis&nbsp;</li>\n<li>Osteomyelitis&nbsp;</li>\n<li>Radiation&nbsp;</li>\n</ul>",
      "question_images": [
        "https://cdn1.dailyrounds.org/uploads/c6a1424ea99b4106878df195ff5d32db.PNG"
      ],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC2941",
      "difficulty": "medium"
    },
    {
      "text": "A 68-year-old male patient presented with multiple fractures. He has been suffering from recurrent infections for the past 6 months. Bone marrow biopsy showed the following. What is the treatment of choice in this condition?",
      "choices": [
        {
          "id": 1,
          "text": "Lenalidomide + bortezomib + dexamethasone"
        },
        {
          "id": 2,
          "text": "Thalidomide + cyclophosphamide"
        },
        {
          "id": 3,
          "text": "Rituximab + cyclophosphamide"
        },
        {
          "id": 4,
          "text": "Bortezomib + cyclophosphamide + dexamethasone"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p>In the above clinical scenario, the symptoms and bone marrow biopsy are characteristic of multiple myeloma.<strong> Lenalidomide</strong> + <strong>bortezomib</strong> +<strong> dexamethasone</strong> is the <strong>treatment of choice</strong> in this condition.&nbsp;</p>\n<p>This combination achieves close to a <strong>100% response</strong>. Hence it is one of the preferred induction regimens in transplant-eligible multiple myeloma patients.</p>\n<p>Other pharmacological agents are used as second-line and have a 90% response rate.&nbsp;Chemotherapy followed by <strong>autologous stem cell transplantation</strong> prolongs overall survival.</p>\n<p>The image below shows a bone marrow biopsy with an increased number of plasma cells.</p><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/c9a0234ddd5945bca2e2420d358c7e43x640x482.JPEG\" alt=\"Explanation Image\"><p>FDA has approved Abecma, the first cell-based gene therapy to treat adult patients with multiple myeloma who have not responded to, or whose disease has returned after, at least four prior lines (different types) of therapy.</p>",
      "question_images": [
        "https://cdn1.dailyrounds.org/uploads/5b0a6da00a7f427fb24f52f9546620a6.JPEG"
      ],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB4208",
      "difficulty": "medium"
    },
    {
      "text": "Which of the following is a proteasome inhibitor?",
      "choices": [
        {
          "id": 1,
          "text": "Lenalidomide"
        },
        {
          "id": 2,
          "text": "Rituximab"
        },
        {
          "id": 3,
          "text": "Cyclophosphamide"
        },
        {
          "id": 4,
          "text": "Bortezomib"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<p><strong>Bortezomib</strong> is a proteasome inhibitor.</p>\n<p>It has a rapid response and is effective in poor-prognosis myeloma.&nbsp;Side effects include <strong>neuropathy</strong> (both peripheral and autonomic). <strong>Subcutaneous</strong> and <strong>weekly</strong> administration can reduce neuropathic side effects.</p>\n<p>Other proteasome inhibitors include <strong>carfilzomib</strong> (second-generation) and <strong>ixazomib</strong>, an oral proteasome inhibitor, used in relapsed disease.</p>\n<p>Option A: Lenalidomide is an immunomodulatory analogue of thalidomide.</p>\n<p>Option B: Rituximab is an anti-CD-20 monoclonal antibody.</p>\n<p>Option C: Cyclophosphamide is an alkylating chemotherapeutic agent.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB4212",
      "difficulty": "medium"
    },
    {
      "text": "A 64-year-old male patient is admitted with complaints of weakness of the extremities, blurry vision, and nose-bleeds. On examination, there is lymphadenopathy and dilatation of the retinal veins. Peripheral smear is given below. Which of the following is false regarding this condition?",
      "choices": [
        {
          "id": 1,
          "text": "Bone marrow >10% lymphoplasmacytoid cells"
        },
        {
          "id": 2,
          "text": "Lytic bone lesions"
        },
        {
          "id": 3,
          "text": "M component in serum >30g/L"
        },
        {
          "id": 4,
          "text": "Increased viscosity of blood"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p>In the above clinical scenario, the hyperviscosity symptoms and rouleaux formation on peripherals smear point to a diagnosis of <strong>Waldenstrom's macroglobulinemia</strong>. It <strong>does not</strong> cause <strong>lytic bone lesions</strong>.</p>\n<p>Waldenstrom's macrogl&ouml;bulinemia is a B-cell malignancy affecting <strong>lymphoplasmacytoid</strong> and <strong>plasma cells</strong>. It is characterized by <strong>high</strong> levels of circulating <strong>IgM antibodies</strong>.</p>\n<p>Clinical features include:</p>\n<ul>\n<li>Hyperviscosity symptoms\n<ul>\n<li>Recurrent infections</li>\n<li><strong>Epistaxis</strong></li>\n<li><strong>Visual disturbances</strong></li>\n</ul>\n</li>\n<li>Peripheral neuropathy - due to myelin-associated glycoprotein causing demyelination.</li>\n<li>Lymphadenopathy</li>\n<li>Hepatosplenomegaly</li>\n<li>Ophthalmoscopic examination may reveal vascular segmentation and dilation of the retinal veins.</li>\n</ul>\n<p>Investigations:</p>\n<ul>\n<li>Bone marrow shows <strong>&gt;10% infiltration</strong> with lymphoplasmacytic cells</li>\n<li>Serum <strong>M component</strong> is &gt;30 g/L (3 g/dL). The size of the IgM paraprotein results in little renal excretion, and only 20% of patients excrete light chains.</li>\n</ul>\n<p>The image below shows rouleaux formation.</p><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/182885ae4286489199a573141b993691x800x600.JPEG\" alt=\"Explanation Image\">",
      "question_images": [
        "https://cdn1.dailyrounds.org/uploads/2b305361d6694819b457aacda727e288.JPEG"
      ],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB4216",
      "difficulty": "medium"
    },
    {
      "text": "A 19-year-old boy presented with progressive shortness of breath, and easy fatiguability for 3 years. His older brother died of cardiac arrest during a football match a few years ago. Further evaluation revealed hypertrophic cardiomyopathy. Biopsy and staining of subcutaneous fat showed the following. What mutation is likely in this patient?",
      "choices": [
        {
          "id": 1,
          "text": "Leukocyte chemotactic factor"
        },
        {
          "id": 2,
          "text": "Transthyretin"
        },
        {
          "id": 3,
          "text": "Light chain"
        },
        {
          "id": 4,
          "text": "Beta 2 microglobulin"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p>The biopsy showing <strong>amyloid deposits</strong> stained by <strong>congo red,&nbsp;</strong>along with family history points to a diagnosis of <strong>familial amyloidosis (AF)</strong>. It is most commonly due to the mutation of the <strong>transthyretin gene</strong> (TTR).</p>\n<p>Amyloidosis is a group of protein misfolding disorders characterized by the <strong>accumulation</strong> of abnormal proteins called <strong>amyloid fibrils</strong> in various organs.</p><hr><h3>Related Pearl: Classification of Amyloidosis</h3><div class=\"page\" title=\"Page 270\">\n<table><colgroup><col /><col /><col /><col /> </colgroup>\n<tbody>\n<tr>\n<td>\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p><strong>Clinicopathologic Category</strong></p>\n</div>\n</div>\n</td>\n<td>\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p><strong>Major Fibril Protein</strong></p>\n</div>\n</div>\n</td>\n<td>\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p><strong>Chemically Related Precursor Protein</strong></p>\n</div>\n</div>\n</td>\n</tr>\n<tr>\n<td colspan=\"3\" rowspan=\"1\">\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p><strong>Systemic (Generalized) Amyloidosis:</strong></p>\n</div>\n</div>\n</td>\n</tr>\n<tr>\n<td>\n<div class=\"layoutArea\">\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p>Immunoglobulin light chain amyloidosis (<strong>primary amyloidosis</strong>)</p>\n<p>Seen in Multiple myeloma and other monoclonal plasma cell proliferation</p>\n</div>\n</div>\n</div>\n</td>\n<td>\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p>AL</p>\n</div>\n</div>\n</td>\n<td>\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p>Immunoglobulin light chains, chiefly &lambda; type</p>\n</div>\n</div>\n</td>\n</tr>\n<tr>\n<td>\n<div class=\"layoutArea\">\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p>Reactive systemic amyloidosis (<strong>secondary amyloidosis</strong>)</p>\n<p>Seen in chronic inflammatory conditions</p>\n</div>\n</div>\n</div>\n</td>\n<td>\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p>AA</p>\n</div>\n</div>\n</td>\n<td>\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p>SAA</p>\n</div>\n</div>\n</td>\n</tr>\n<tr>\n<td>\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p>Hemodialysis-associated amyloidosis</p>\n<p>Seen in chronic renal failure</p>\n</div>\n</div>\n</td>\n<td>\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p>A&beta;2m</p>\n</div>\n</div>\n</td>\n<td>\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p>&beta;2-microglobulin</p>\n</div>\n</div>\n</td>\n</tr>\n<tr>\n<td colspan=\"3\" rowspan=\"1\">\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p><strong>Hereditary Amyloidosis:</strong></p>\n</div>\n</div>\n</td>\n</tr>\n<tr>\n<td>\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p>Familial Mediterranean fever</p>\n</div>\n</div>\n</td>\n<td>\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p>AA</p>\n</div>\n</div>\n</td>\n<td>\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p>SAA</p>\n</div>\n</div>\n</td>\n</tr>\n<tr>\n<td>\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p>Familial amyloidotic neuropathies</p>\n</div>\n</div>\n</td>\n<td>\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p>ATTR</p>\n</div>\n</div>\n</td>\n<td>\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p>Mutated transthyretin</p>\n</div>\n</div>\n</td>\n</tr>\n<tr>\n<td>\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p>Systemic senile amyloidosis</p>\n</div>\n</div>\n</td>\n<td>\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p>ATTR</p>\n</div>\n</div>\n</td>\n<td>\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p>Normal transthyretin</p>\n</div>\n</div>\n</td>\n</tr>\n<tr>\n<td colspan=\"3\" rowspan=\"1\">\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p><strong>Localized Amyloidosis:</strong></p>\n</div>\n</div>\n</td>\n</tr>\n<tr>\n<td>\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p>Senile cerebral amyloidosis</p>\n<p>Seen in Alzheimer's disease</p>\n</div>\n</div>\n</td>\n<td>\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p>A&beta;</p>\n</div>\n</div>\n</td>\n<td>\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p>APP</p>\n</div>\n</div>\n</td>\n</tr>\n<tr>\n<td>\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p>Endocrine disorders like Type 2 diabetes</p>\n</div>\n</div>\n</td>\n<td>&nbsp;</td>\n<td>&nbsp;</td>\n</tr>\n<tr>\n<td>\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p>Medullary carcinoma thyroid</p>\n</div>\n</div>\n</td>\n<td>\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p>A Cal</p>\n</div>\n</div>\n</td>\n<td>\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p>Calcitonin</p>\n</div>\n</div>\n</td>\n</tr>\n<tr>\n<td>\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p>Islets of Langerhans</p>\n</div>\n</div>\n</td>\n<td>\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p>AIAPP</p>\n</div>\n</div>\n</td>\n<td>\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p>Islet amyloid peptide</p>\n</div>\n</div>\n</td>\n</tr>\n<tr>\n<td>\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p>Isolated atrial amyloidosis</p>\n</div>\n</div>\n</td>\n<td>\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p>AANF</p>\n</div>\n</div>\n</td>\n<td>\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p>Atrial natriuretic factor</p>\n</div>\n</div>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n</div>",
      "question_images": [
        "https://cdn1.dailyrounds.org/uploads/d64e4ec50565419d8343de7cce3db658.JPEG"
      ],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB4218",
      "difficulty": "medium"
    },
    {
      "text": "A 60-year-old man presented with progressive weight loss, generalized edema. On evaluation, he had nephrotic range proteinuria, macroglossia, and raccoon eyes. What is the most probable diagnosis?",
      "choices": [
        {
          "id": 1,
          "text": "Solitary plasmacytoma"
        },
        {
          "id": 2,
          "text": "Waldenstrom's macroglobulinemia"
        },
        {
          "id": 3,
          "text": "Amyloidosis"
        },
        {
          "id": 4,
          "text": "IgA nephropathy"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p>The patient has non-specific symptoms, which along with&nbsp;<strong>macroglossia</strong> and <strong>raccoon eyes&nbsp;</strong>are suggestive&nbsp;of <strong>amyloidosis</strong>.</p>\n<p>Clinical features include:</p>\n<ul>\n<li>Fatigue</li>\n<li>Weight loss</li>\n<li>Nephrotic range proteinuria due to <strong>renal amyloidosis</strong>&nbsp;and&nbsp;is associated with hypoalbuminemia</li>\n<li><strong>Cutaneous ecchymoses</strong> around the eyes are called the '<strong>raccoon-eye' sign</strong>. Due to easy bruising as a result of amyloid deposits or deficiency of clotting factor X.</li>\n</ul>\n<p>&nbsp;</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB4232",
      "difficulty": "medium"
    },
    {
      "text": "Which of the following is the most commonly involved organ in amyloidosis?",
      "choices": [
        {
          "id": 1,
          "text": "Heart"
        },
        {
          "id": 2,
          "text": "Kidneys"
        },
        {
          "id": 3,
          "text": "Liver"
        },
        {
          "id": 4,
          "text": "Spleen"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p>The <strong>kidneys</strong> are the <strong>most</strong> frequently <strong>involved</strong> organ in amyloidosis and are affected in 70&ndash;80% of patients.</p>\n<p>The <strong>heart</strong> is the <strong>second most</strong> commonly affected organ (50&ndash;60% of patients).</p>\n<p>The spleen is frequently involved, and there may be functional hyposplenism in the absence of significant splenomegaly.&nbsp;</p>\n<p>Liver involvement causes cholestasis.</p>\n<p>Macroglossia, a pathognomonic sign of AL amyloidosis is seen in only 10% of patients.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB4222",
      "difficulty": "easy"
    },
    {
      "text": "What is the leading cause of death in patients with primary amyloidosis?",
      "choices": [
        {
          "id": 1,
          "text": "Renal failure"
        },
        {
          "id": 2,
          "text": "Cardiac disease"
        },
        {
          "id": 3,
          "text": "Liver failure"
        },
        {
          "id": 4,
          "text": "Recurrent infections"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p><strong>Cardiac disease</strong> is the <strong>leading cause</strong> of <strong>death</strong> from primary amyloidosis.&nbsp;</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB4230",
      "difficulty": "medium"
    }
  ]
}